-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"The FDA approval of this new combination therapy is an exciting development for all of us with melanoma," Dr.
Checkpoint inhibitor immunotherapy helps cancer evade the body's immune system by blocking specific proteins on the surface of cells
In the relative-047 trial, 714 patients with previously untreated advanced melanoma were randomized to receive relatlimab + nivolumab or nivolumab monoclonal antibody
Nivolumab acts on a protein called PD-1, which is FDA-approved to treat melanoma and several other cancers
The antitumor effects of LAG-3 blockade were initially discovered by scientists at the Bloomberg Kimmel Institute
Journal Reference :
Hussein A.